Melanoma-on-a-chip model for anticancer drug injecting delivery method

Area of Science:

• Biomedical Engineering
• Oncology
• Drug Development

Background:

• Traditional skin models face challenges in pharmaceutical and cosmetic product development.
• Organ-on-a-chip systems, especially for skin, show promise but lack melanoma study integration.
• A need exists for advanced models to study melanoma and test anti-cancer therapies.

Purpose of the Study:

• To develop and validate a novel skin-on-a-chip device for melanoma research.
• To assess the efficacy of an anticancer drug (Gemcitabine) using this microfluidic model.
• To establish a high-fidelity platform for real-time drug testing and melanoma monitoring.

Main Methods:

• Designed a two-chamber microfluidic skin-on-a-chip device.
• Established a 3D co-culture of fibroblasts, keratinocytes, and melanoma cells.
• Administered the anticancer drug Gemcitabine via an integrated injection system.

Main Results:

• Observed a significant impact on co-culture cell distribution.
• Demonstrated a decrease in melanoma (cancerous) cell population post-Gemcitabine administration.
• Validated the chip's effectiveness for anti-melanoma therapy testing.

Conclusions:

• The developed skin-on-a-chip is an effective model for studying melanoma.
• The microfluidic platform facilitates real-time monitoring of anti-melanoma drug efficacy.
• This technology offers an enhanced fidelity alternative for drug development and melanoma research.